Antitumor activity of novel tricyclic pyrone analogs in murine leukemia cells in vitro

Anticancer Research

Volumn 17, Issue 4 A, 1997, Pages 2427-2434

  Perchellet, Jean Pierre ^a,b   Newell, Steven W ^a   Ladesich, James B ^a   Perchellet, Elisabeth M ^a   Chen, Yi ^b   Hua, Duy H ^b   Kraft, Susan L ^b   Basaraba, Randall J ^b   Omura, Satoshi ^c   Tomoda, Hiroshi ^c  

^a Anti Cancer Drug Laboratory   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

DNA synthesis; L1210 cells; Tricyclic pyrones; Tumor cell growth

Indexed keywords

ANTINEOPLASTIC AGENT; PENTAHYDRO 3 ARYL 1 OXOPYRANO[4,3 B][1]BENZOPYRAN; PYRONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; GROWTH INHIBITION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; GROWTH INHIBITORS; LEUKEMIA L1210; PYRONES;

EID: 0030877708     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tomoda H, Nishida H, Kim YK, Obata R, Sunazuka T, Omura S, Bordner J, Guadliana M, Dormer PG and Smith AB: Relative and absolute stereochemistry of pyripyropene A, a potent, bioavailable inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT). J Am Chem Soc 116: 12097-12098, 1994.
2. Bell FP: Arterial cholesterol esterification by acyl-CoA:cholesterol acyltransferase: its possible significance in atherogenesis and its inhibition by drugs. In: Fears R (ed.), Pharmacological Control of Hyperlipidaemia. JR Prous Science Publishers, Barcelona, Spain, pp. 409-422, 1986.
3. Heider JG: Agents which inhibit cholesterol esterification in the intestine and their potential value in the treatment of hypercholesterolaemia. In: Fears R (ed.), Pharmacological Control of Hyperlipidaemia. JR Prous Science Publishers, Barcelona, Spain, pp. 423-438, 1986.
4. Sliskovic DR and White AD: Therapeutic potential of ACAT inhibitors as lipid lowering and antiatherosclerotic agents. Trends Pharmacol Sci 12: 194-199, 1991.
5. Arvanov VL, Ling KH, Chen RC and Tsai MC: Effects of territrem-B on cholinergic responses of snail neuron. Neurosci Lett 152: 69-71, 1993.
6. Lee CY, Ling KH and Wang CT: The effect of territrem A and territrem B on human platelet function. Thromb Haemostasis 65: 1078, 1991.
7. Ling KH, Yang CK and Peng FT: Territrems, tremorgenic mycotoxins of Aspergillus terreus. Appl Environ Microbiol 37: 355-357, 1979.
8. Ling KH, Liou HH, Yang CM and Yang CK: Isolation, chemical structure, acute toxicity, and some physicochemical properties of territrem C from Aspergillus terreus. Appl Environ Microbiol 47: 98-100 1984.
9. Omura S, Kuno F, Otoguro K, Sunazuka T, Shiomi K, Masuma R and Iwai Y: Arisugacin, a novel an selective inhibitor of acetylcholinesterase from Penicillium sp. FO-4259. J Antibiotics 48: 745-746, 1995
10. Summers WK, Majovski LV, Marsh GM, Tachiki K and Kling A: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzeimer type. N Engl J Med 315: 1241-1245, 1986
11. Perchellet JP, Newell SW, Ladesich JB, Perchellet EM, Chen Y and Hua DH: Antitumor activity of novel tricyclic pyrone analogs in vitro. Proc Am Assoc Cancer Res 38: in press, 1997.
12. Liu LF: DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 58: 351-375, 1989.
13. Potmesil M: Camptothecins: from bench research to hospital wards. Cancer Res 54: 1431-1439, 1994.
14. Wall ME and Wani MC: Camptothecin and taxol: discovery to clinic. 13th Bruce F Cain Memorial Award Lecture. Cancer Res 55: 753-760, 1995.
15. Gao XM, Perchellet EM, Davis AW, Newell SW, Hua DH and Perchellet JP: Characterization of the antitumor-promoting activity of camptothecin in SENCAR mouse skin. Carcinogenesis 17: 1141-1148, 1996.
16. Gao XM, Perchellet EM, Davis AW, Newell SW, Chen G, Hua DH and Perchellet JP: Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo. Int J Cancer 66: 496-505, 1996.
17. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260: 14873-14878, 1985.
18. Madden KR and Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. Cancer Res 52: 525-532, 1992.
19. Holm C, Covey JM, Kerrigan D and Pommier Y: Differential requirements of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 49: 6365-6368, 1989.
20. Tsao YP, Russo A, Nyamuswa G, Silber R and Liu LF: Interaction between replication fork and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res 53: 5908-5914, 1993.
21. Ryan AJ, Squires S, Strutt HL, Evans A and Johnson RT: Different fates of camptothecin-induced replication fork-associated DNA double-strand breaks in mammalian cells. Carcinogenesis 15: 823-828, 1994.
22. Pantazis P, Kozielski AJ, Vardeman DM, Petry ER and Giovanella BC: Efficacy of comptothecin congeners in the treatment of human breast carcinoma xenografts. Oncology Res 5: 273-281, 1993.
23. Hsiang YH, Lihou MG and Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
24. Ryan AJ, Squires S, Strutt HH and Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double-strand breaks in replicating DNA. Nucleic Acids Res 9: 3295-3300, 1991.
25. Squires S, Ryan AJ, Strutt HH and Johnson RT: Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double-strand breaks in nascent DNA. Cancer Res 55: 2012-2019, 1993.
26. cdc2/cyclin B. Cancer Res 52: 1823-1829, 1992.
27. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R and Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-S-camptothecin. Cancer Res 51: 3052-3055, 1991.